On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > COLUMN
COLUMN
-
The Crisis That Ignited a Workplace Revolution
July 6, 2020
-
Smart Strategies for Building Your Dream Team
March 17, 2020
-
A Peek into the Digital Pharmaceutical Industry
November 21, 2019
-
Plant the Seeds of Success when Battling a Crisis
September 30, 2019
-
Practice Makes Perfect - Even in Marketing!
August 19, 2019
-
Failing Isn’t the Issue. What You Do Next Is All that Counts
July 26, 2019
-
Big Question Mark to Pricey Drug Bashing
July 12, 2019
-
The Science Behind Stage Fright, and How You Can Overcome It
June 28, 2019
-
The Power in Teaching Your Team “How to Speak”
May 28, 2019
-
Unlock Hidden Talent by Hiring for These Four Traits
May 10, 2019
-
No Drug “Reviews” for 1st Time in 2 Years
April 22, 2019
-
6 Core Elements of Recruitment Mastery
March 22, 2019
-
Is Japan’s Cost-Effectiveness Assessment Scheme Cost Effective?
February 27, 2019
-
Why Top-Tier Recruiters Must Embrace Their Creative Side
January 31, 2019
-
Expat Truths from the Japanese Medical Device World
December 3, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Why Did the Project Take so Long?
November 16, 2018
-
Finding Captains in Your Organization
October 12, 2018
-
Riding the Trend: Staffing Pharma Startups in Japan
September 7, 2018
-
How Having a Great CSR Program Can Help with Recruiting and Retaining Top Talent
August 16, 2018
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…